Robert Stratta to Muromonab-CD3
This is a "connection" page, showing publications Robert Stratta has written about Muromonab-CD3.
Connection Strength
0.583
-
Stratta RJ, Taylor RJ, Weide LG, Sindhi R, Sudan D, Castaldo P, Cushing KA, Frisbie K, Radio SJ. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Transplant Proc. 1996 Apr; 28(2):917-8.
Score: 0.136
-
Stratta RJ, Taylor RJ, Lowell JA, Bynon JS, Cattral MS, Frisbie K, Miller S, Brennan DC. OKT3 induction in 100 consecutive pancreas transplants. Transplant Proc. 1994 Apr; 26(2):546-7.
Score: 0.119
-
Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Reed EC, Langnas AN, Pillen TJ, Shaw BW. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992 Jan; 127(1):55-63; discussion 63-4.
Score: 0.101
-
Stratta RJ. Experience with azathioprine withdrawal after simultaneous kidney-pancreas transplantation. Transplant Proc. 1998 Jun; 30(4):1353-4.
Score: 0.040
-
Stratta RJ, Sudan R, Sudan D. Long-term outcomes in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 1998 Jun; 30(4):1564-5.
Score: 0.040
-
Sindhi R, Stratta RJ, Taylor RJ, Lowell JA, Sudan D, Castaldo P, Bynon JS, Pillen TJ. Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction. Transplant Proc. 1995 Dec; 27(6):3016-7.
Score: 0.033
-
Stratta RJ, Taylor RJ, Ozaki CF, Bynon JS, Langnas AN, Shaw BW. Combined pancreas-kidney transplantation versus kidney transplantation alone: analysis of benefit and risk. Transplant Proc. 1993 Feb; 25(1 Pt 2):1298-301.
Score: 0.027
-
Taylor RJ, Stratta RJ, Zorn BH, Langnas AN, Shaw BW. Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management. Transplant Proc. 1991 Oct; 23(5):2317-8.
Score: 0.025
-
Stratta R, Shaefer M, Bradshaw K, Wood R, Langnas A, Zetterman R, Donovan J, Sorrell M, Markin R, Shaw BW. Experience with OKT3 after orthotopic liver transplantation. Transplant Proc. 1991 Jun; 23(3):1970.
Score: 0.024
-
Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, Hardinger K, Alloway RR, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience. Clin Transplant. 2002; 16 Suppl 7:34-44.
Score: 0.013
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):635-7.
Score: 0.007
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):679-88.
Score: 0.007
-
Saito S, Stratta RJ, Grazi GL, Castaldo P, Langnas AN, Wood RP, Shaw BW. Effect of the HLA-DRw6 antigen in liver transplantation. Transplant Proc. 1991 Feb; 23(1 Pt 2):1430-1.
Score: 0.006
-
D'Alessandro AM, Pirsch JD, Stratta RJ, Sollinger HW, Kalayoglu M, Maki DG, Belzer FO. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation. 1989 Feb; 47(2):297-300.
Score: 0.005